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Abstract
Background: According to French national recommendations, the detection of a patient colonized with
glycopeptide-resistant enterococci (GRE) leads to interruption of new admissions and transfer of contact patients
(CPs) to another unit or healthcare facility, with weekly screening of CPs.
Findings: We evaluated the medical and economic impact of a pragmatic adaptation of national guidelines
associated with a real-time PCR (RTP) (Cepheid Xpert™ vanA/vanB) as part of the strategy for controlling GRE spread
in two medical wards. Screening was previously performed using chromogenic selective medium (CSM). Turn
around time (TAT), costs of tests and cost of missed patient days were prospectively collected. In February 2012, the
identification of GRE in one patient in the diabetology ward led to the screening of 31 CPs using CSM; one second-
ary case was identified in a CP already transferred to the Nephrology ward. Awaiting the results of SCM (median
TAT, 70.5 h), 41 potential patient days were missed, due to interruption of admissions. The overall cost (screening
tests + missing patient.days) was estimated at 14, 302.20 €. The secondary case led to screening of 22 CPs in the
Nephrology ward using RTP. Because of a short median TAT of 4.6 h, we did not interrupt admissions and patients’
transfers. Among 22 CPs, 19 (86%) were negative for vanA, 2 were positive for vanB and 3 had invalid results need-
ing CSM. The overall cost of the strategy was estimated at 870.40 € (cost of screening tests only), without missing
patient days.
Conclusion: The rapid PCR test for vanA-positive GRE detection both allowed rapid decision about the best
infection control strategy and prevented loss of income due to discontinuation of patient transfers and admissions.
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Findings
Glycopeptide-resistant in enterococci (GRE) have risen
rapidly in recent years, posing a particular threat in
healthcare facilities (HCF) [1]. Several countries have is-
sued national guidelines for controlling their spread
[2,3]. French recommendations consist of strict contact
precautions for colonized patients in screening and iso-
lation of contact patients (i.e. sharing the nursing staff
with colonized patients), with neither transfers of pa-
tients nor admissions to the involved ward until three
negative weekly screening tests [4]. The percentage of
GRE (mostly vanA genotypes) among E. faecium blood-
stream infections in France declined from a 3.2% peak in
2006 to a plateau at about 1% afterwards [5]. However,
this strategy is burdensome and limits the use of hospital
services, resulting in both missed opportunities for pa-
tients and decreased income for HCF.
The cornerstone of those control measures is the early
recognition of GRE colonized patients by rapid and ac-
curate screening tests. The Xpert™ system (Cepheid,
Sunnyvale, CA) is a one-step PCR assay providing
results generally in less than 1 h with a high negative
predictive value (NPV) for GRE detection in rectal speci-
mens. However, the carriage of vanB gene by other or-
ganisms than E. faecium gives a weak positive predictive
value to the test [6]. The purpose of this study was to
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evaluate the medical and economic impact of the
Cepheid Xpert™ vanA/vanB real-time PCR assay as part
of a strategy for controlling GRE spread in two medical
wards.
Patients and methods
Study design
The present study is a description and evaluation of two
control measures. The first was applied for an index case
in a diabetology ward and included a screening based on
culture technique. The second used a PCR assay and
was applied for a secondary case hospitalized in a Neph-
rology ward.
Local recommendation
We adapted French national recommendations based on
the pragmatic following rules: (i) if no new GRE case
was identified by initial cross-sectional screening of con-
tact patients, patient transfer to other wards or HCFs
were allowed, as well as the admission of new patients.
Contact patients transferred to another ward were to be
placed in single room with contact precautions in the
downstream ward until the result of two subsequent
screening tests was available. (ii) If another GRE-positive
case was identified by cross-sectional screening, national
guidelines were to be followed scrupulously.
Microbiological tests
Two simultaneous culture techniques were used: (i) One
rectal swab inoculated in enrichment broth (AES VRE)
incubated 24 hours, and then subcultured onto the
chromogenic medium (Oxoid Brillance VRE) incubated
aerobically at 37°C and read after 24 and 48 h; (ii) a
second swab was directly plated on the same type of
medium. Enterococcus faecium were identified using a
mass spectrometry assay (MALDI-TOF-MS system).
Strains were suspected as GRE in case of minimum
inhibitory concentrations (MICs) >8 mg/L for vanco-
mycin and/or teicoplanin using E-test strips (BioRad).
Vancomycin-resistance genotypes were identified using a
DNA strip assay (GenoType Enterococcus; Hain Life-
science GmbH).
For the molecular diagnosis, Xpert vanA PCR assay
was performed by the manufacturer’s instructions (Ce-
pheid) using rectal swabs. Considering the high negative
predictive value of the test, the patient was considered at
low risk to be colonized if the result was negative for the
vanA and vanB genes. Otherwise, conventional culturing
was performed to confirm or disprove the presence of
GRE. Cultures were also performed in case of amplifica-
tion inhibitors in the sample.
Time and cost analysis
Time required for each step of the microbiological ana-
lysis was collected prospectively. The cost of screening
was computed based on the use of material resources
needed and personnel costs on the basis of the hourly
salary of a senior staff member.
We estimated the costs attributable to the decreased
occupancy by multiplying the number of missed patient-
days (difference between admission capacity and the
number of admitted patients when a GRE-positive pa-
tient was identified) by the mean cost billed per hospital
day (total amount billed in 2011 based on French
Diagnosis-Related Groups divided by the number of
patient-days in 2011) [7].
Results
Investigation around the first case: local recommendation
and culture method
On 2 February, 2012, a 68-year-old man was admitted to
the diabetology ward for the management of compli-
cated type-2 diabetes.
On 27 February, an E. faecium strain highly resistant
to vancomycin and teicoplanin was cultured from a
wound in the right foot PCR confirmed the presence of
the vanA gene. The diabetology ward has 32 beds in 16
double rooms. All 31 patients hospitalized in the ward
were considered contact patients of the first case. At this
time, the Xpert™ vanA/vanB PCR had been recently
introduced in our laboratory and was used on an excep-
tional basis to screen the two patients who had shared
the room of the first case patient, one of whom was
PCR-positive. The investigation of this secondary case
will be described in the corresponding paragraph.
On 28 February, rectal swabs were obtained from the
31 contact patients of the first case and cultured accord-
ing to standard techniques. Transfers to other units or
HCFs and admissions were stopped pending the results
of the rectal-swab cultures. However, 17 of the 31 con-
tact patients were sampled and discharged home over
the next two days.
On 29 February, the two colonized patients (the initial
case and the secondary case identified from the same
room by PCR) and 13 contact patients were cohorted in
a separate area of the ward and cared for by dedicated
staff to prevent cross transmissions.
As shown in Table 1, the median turnaround times
(TAT) for culture techniques was 70.5 hours. Of the 31
screened patients, one was found colonized with GRE
corresponding to the secondary case previously identi-
fied by PCR (see above). None of the 17 patients dis-
charged home was finally found to be colonized.
On 1 March, new admissions were allowed in a differ-
ent area of the ward. Two additional weekly screening of
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Table 1 Description of results, time and cost of
microbiological analysis during two phases of the
investigation of two cases of glycopeptide-resistant
Enterococci
Investigation of the
first case in the
diabetology unit
Investigation of a
secondary case in the
nephrology unit
(n=31 patients) (n=22 patients)
Test Results, n (%)
Cepheid Xpert™
vanA/vanB assay:
Negative PCR 1 (3)a 17 (77)
Positive vanA 1 (3)a 0 (0)
Positive vanB and
culture showing
susceptible strain
- 2 (9)
PCR invalid then
negative culture
- 2 (9)
PCR invalid then
culture showing
susceptible stain
- 1 (5)
Culture after
enrichment using
chromogenic
medium:
Negative culture 26 (84) -
Culture positive for
GRE strainb
1 (3)a -
Culture positive for
susceptible
Enterococcusc
4 (13) -
Turn-around time
(hours, median
[Q1-Q3])
From sampling,
to sample reception
2.6 (1.7-2.6) 2.8 (1.1 – 3.8)
From sample
reception,
to inoculation
or preparation
2.3 (2.2– 2.4) 1.3 (0.5 – 2.3)
From inoculation
or preparation,
to results
65.5 (65.5– 65.5) 1 (0.9-1.1)
From sample
reception, to results
67.8 (68.4 – 67.9) 6.22 (3.7 – 8.2)
From sampling,
to results
70.5 (69.4 – 70.5) 4.6 (4.0 – 18.9)
Maximal time to
obtain all results
70.5 90.0
Cost of
microbiological
analysis (€)
Cepheid Xpert™
vanA/vanB assay:
Cost of 1 cartridge - 35.60
Cost of 1 test - 37.30
Table 1 Description of results, time and cost of
microbiological analysis during two phases of the
investigation of two cases of glycopeptide-resistant
Enterococci (Continued)
Culture with
chromogenic
medium and
enrichment
Cost of a negative
culture
4.80 -
Cost of a doubtful
culturec
13.40 -
Cost of a doubtful
cultured
23.50 -
Cost of a positive
cultureb
117.80 -
Total cost of
microbiological
testing
333.50 870.40
Loss of income
Cost per weighted
case per day in 2011e
340.70 426.00
Scenario 1:
Implementation of
local guidelines
Patient-days
lost f
41 0
Estimated
loss of income (€)
13,968.70 0
Scenario 2:
Implementation of
national guidelines
Patient-days
lostf
250 0
Estimated
loss of income (€)
85,175.00 0
Overall loss of
income (€)
13,968.70 to 85,175.00 0
Overall cost of the
strategy (€)
14,302.20 to 86,175.50g 870.40 to 2,611.20g
PCR, polymerase chain reaction; GRE, Glycopeptide-Resistant Enterococci ; Q1, First
quartile; Q3, Third quartile.
aReal-time PCR assay performed on an exceptional basis to screen the two pa-
tients who shared the room of the first patient in the diabetology ward.
bPositive culture with identification of E. faecium by mass spectrometry assay,
MICs >8 mg/L for vancomycin and/or teicoplanin on E-test strips, antibiotic
susceptibility testing by disk diffusion in solid media for clinical purpose, and
detection of the vancomycin resistance genotype by DNA strip assay.
cPositive culture with identification of Enterococcus faecium by mass spectrometry
assay with MICs ≤8 mg/L for vancomycin and/or teicoplanin on E-test strips.
dPositive culture with identification of E. faecium by mass spectrometry assay,
MICs >8 mg/L for vancomycin and/or teicoplanin on E-test strips, and anti-
biotic susceptibility testing by disk diffusion in solid media for clinical purpose.
eEstimated costs of inpatient care based on reimbursement rates of the diagnosis-
related group. In France, the diagnosis-related group price is calculated by multiply-
ing standard amounts for operating and capital expenses found in yearly surveys by
a national “weight” associated with the DRG for each hospitalisation. The weighting
takes in account variations due to geographic area and atypical observations.
fNumber of missed patient-days due to the interruption of patients’ transfers
and admissions.
gCosts estimation assuming the strict implementation of French national
guidelines with three weekly screening of patients.
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contact patients performed using the same culture
method identified no additional cases.
This local GRE control protocol resulted in a 72-hour
period without admissions or transfers, with 41 missed
patient-days and €13,968 of lost income (Table 1). Fol-
lowing the national guidelines would have resulted in 15
days without admissions or transfers, with 250 patient-
days of loss of activity and €85,175 of lost income. The
cost of microbiological testing using the culture method
was €333.50. The global estimated costs were therefore
€14,302 and €86,175 with the local and national guide-
lines, respectively.
Investigation around the secondary case: local
recommendation and PCR assay
As described previously, a secondary case was rapidly
identified using the Xpert™ vanA/vanB PCR. This patient
stayed in the nephrology ward from 1 January to 20 Feb-
ruary, 2012. The nephrology ward has 28 beds with 12
double and 4 single rooms. On 28 February, the 22 pa-
tients hospitalized during the same period and still
present in the nephrology ward were considered to be
contact patients and were screened for GRE by rectal
swabbing. We decided to use the GeneXpert™ test for
this purpose and, given the TAT with this test, to con-
tinue transfers and admissions as usual unless another
GRE-positive patient was identified. The median time to
results was 4.6 hours after sampling (Table 1). However,
because only a four-site GeneXpert™ system was avail-
able, the results for all 22 patients were obtained 9.5
hours after sampling, and decision about the GRE-
control strategy was therefore made at the end of the
day. None of the contact patients had vanA-positive
strains. Consequently, transfers and admissions were
continued. The overall cost of PCR testing for vanA-
positive GRE was €870.40.
Discussion
This observational study showed that using the rapid
PCR test for vanA-positive GRE detection both allowed
rapid decisions about the best infection control strategy
and prevented loss of income due to discontinuation of
patient transfers and admissions. To our knowledge, our
study is the first to precisely evaluate the impact of rapid
PCR for decision making in a context of GRE outbreak.
French authorities have issued strict guidelines for
controlling highly-resistant bacteria such as GRE and
carbapenemase-producing enterobacteriaceae [4]. These
guidelines are based on the assumption that successfully
controlling emerging pathogens will ultimately be cost-
effective [8,9]. However, these strict guidelines result in
significant loss of healthcare activity, as patient transfers
and admissions are stopped pending results of repeated
tests to identify secondary cases are available. Our
locally-adapted national guidelines are based on a prag-
matic attitude. In a context of fortuitous GRE identifica-
tion, the epidemic potential is assessed using the first
cross sectional screening. Duration of restrictions in pa-
tient transfers and admissions depend on the rapidity to
obtain screening results. We calculated that a single
GRE case handled according to local recommendations
resulted in a loss of €14,302 for the diabetology ward, as-
suming the use of standard culture methods. Had the
national recommendations been followed, the maximal
loss would have been €86,175. However, cohort nursing
of the colonized and contact patients would have re-
sulted in lower costs. In both situations, rapid PCR
screening was estimated to result in substantial cost
savings.
Rapid GRE detection using the Xpert™ vanA/vanB
PCR has several advantages. First, the time to results is
approximately one hour from arrival of the specimen at
the laboratory. However, simultaneous screening of nu-
merous patients requires a platform equipped with sev-
eral modules. Second, the GeneXpert™ system has a high
NPV for vanA and vanB [10]. However, other normal in-
habitants of the gut flora may exhibit vanB genes, result-
ing in a lower NPV and requiring conventional cultures
in case of vanB positive PVR assay.
The main limitations of our study are the observa-
tional design and the small number of cases and units in
the cluster.
In conclusion, a rapid real-time PCR assay contributes
to decision-making regarding GRE control measures and
resulted in substantial cost savings. Additional studies
on a larger scale and with control groups are required to
confirm our results.
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